Advanced Search
Contact | Corporate | Help

Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced Non-small Cell Lung Cancer (NSCLC) and (EGFR) Mutations

Sponsors:
  • Massachusetts General Hospital
  • Dana-Farber Cancer Institute
  • Beth Israel Deaconess Medical Center
  • Genentech
Phases:
  • Phase II
IndicationsAcronym:
  • Non-small Cell Lung Cancer
Age Groups:
  • Adult
  • Senior
Gender:
Both
Names:
  • Drug: Erlotinib
  • Drug: Hydroxychloroquine
Enrollment:
76

Additional information about NCT00977470.


SourceSolution © 2008-2012